 | • レポートコード：MRC2203A166 • 出版社/出版日：Mordor Intelligence / 2022年3月15日 • レポート形態：英文、PDF、116ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本市場調査レポートでは、世界の子宮頸がん診断・治療市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、診断検査別（パパニコロウ塗抹検査、HPV検査、コルポスコピー、生検・子宮頸管内掻爬術、その他）分析、治療別（アバスチン（ベバシズマブ）、ブレノキサン（ブレオマイシン）、ハイカムチン（トポテカン塩酸塩）、ゲムシタビン-シスプラチン、ワクチン）分析、エンドユーザー別（病院、専門クリニック、がん・放射線治療センター、診断センター）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来傾向など、以下の構成でまとめました。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の子宮頸がん診断・治療市場規模：診断検査別（パパニコロウ塗抹検査、HPV検査、コルポスコピー、生検・子宮頸管内掻爬術、その他） ・世界の子宮頸がん診断・治療市場規模：治療別（アバスチン（ベバシズマブ）、ブレノキサン（ブレオマイシン）、ハイカムチン（トポテカン塩酸塩）、ゲムシタビン-シスプラチン、ワクチン） ・世界の子宮頸がん診断・治療市場規模：エンドユーザー別（病院、専門クリニック、がん・放射線治療センター、診断センター） ・世界の子宮頸がん診断・治療市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Abbott Laboratories、Bristol-Meyrs Squibb Company、GlaxoSmithKline PLC、…） ・市場機会・将来傾向 |
The factors propelling the growth of the cervical cancer diagnostics and therapeutics market are favorable government initiatives toward cervical cancer prevention, growing prevalence of cervical cancer, increasing awareness regarding early diagnosis, and strong R&D from key players of cervical cancer diagnosis and drugs.
Key Highlights
- The market studied has been witnessing considerable growth, which is attributed to the increasing prevalence of cervical cancer among women worldwide. According to the World Health Organization (WHO), more than 270,000 women die every year due to cervical cancer. The cervical cancer mortality rate is higher in developing countries, due to improper detection at early stages of the disease. With the rising adoption of cervical cancer diagnostic tests for the early detection of cervical cancer, the market is expected to grow.
- Increasing awareness among the general population regarding the care, prevention, and treatment of cervical cancer, rise in certain behaviors, such as sex with multiple partners and smoking, certain genetic factors, and weak immune system are all linked to the growth of the cervical cancer diagnostics and therapeutics market.
- Awareness programs have helped in the growth of the market. For instance, Medicaid, the popular government insurance program, covers the screening for cervical cancers. Medicare, another widely used insurance, covers Pap test, pelvic exam, and clinical breast exam for cervical cancer screening every two years. These programs were found to be responsible for the growth of the overall market.
Key Market Trends
The Pap Smear Test Segment is Expected to Hold a Major Market Share
- Pap smear test, the most effective tool for the diagnosis of HPV, was found to be the most revenue-generating segment.
- According to the World Health Organization (WHO), cervical cancer is the fourth most frequent cancer in women, with an estimated 570,000 new cases in 2018, which represents 6.6% of all female cancers.
- Moreover, approximately 90% of deaths from cervical cancer occurred in low- and middle-income countries.
- Factors, such as the increasing prevalence of HPV infection in women and the deficiency of the HPV vaccine, which does not cover all types of HPV infections, are promoting the growth of the market.
North America is Expected to Hold a Significant Share in the Market
- North America is the largest market for cervical cancer diagnostics and therapeutics. The large market share is attributed to the high awareness about disease prevention among women in the region, as well as to the many initiatives launched to prevent cervical cancer, which have increased the reach of insurance coverage for cervical screening tests, especially for low-income women.
- Asia-Pacific, the fastest-growing market for cervical cancer diagnostic tests, attributes its growth to the increasing prevalence of cervical cancer in developing countries, including China, India, Malaysia, Japan, South Korea, and Australia.
Competitive Landscape
The cervical cancer diagnostics and therapeutics market is fragmented, competitive, and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Companies are currently focusing on developing advanced techniques for diagnosis, such as liquid-based cytology. Some of the companies currently dominating the market are Abbott Laboratories, Bristol-Meyrs Squibb Company, GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc., Qiagen NV, Advaxis Inc., Becton, Dickinson and Company, and F. Hoffmann-La Roche Ltd.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Favorable Government Initiatives toward Cervical Cancer Prevention
4.2.2 Growing Prevalence of Cervical Cancer
4.2.3 Increasing Awareness Regarding Early Diagnosis
4.2.4 Strong R&D from Key Players for Cervical Cancer Diagnosis and Drugs
4.3 Market Restraints
4.3.1 Economic Constraints in Many Countries to Adopt Regular Testing Procedures
4.3.2 High Cost of Cancer Therapies
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Diagnostic Test
5.1.1 Pap Smear Test
5.1.2 HPV Test
5.1.3 Colposcopy
5.1.4 Biopsy and Endocervical Curettage
5.1.5 Other Diagnostic Tests
5.2 By Therapeutics
5.2.1 Avastin (Bevacizumab)
5.2.2 Blenoxane (Bleomycin)
5.2.3 Hycamtin (Topotecan Hydrochloride)
5.2.4 Gemcitabine-Cisplatin
5.2.5 Vaccines
5.2.5.1 Gardasil
5.2.5.2 Cevarix
5.2.6 Other Therapeutics
5.3 By End User
5.3.1 Hospitals
5.3.2 Specilty Clinics
5.3.3 Cancer and Radiation Therapy Centers
5.3.4 Diagnostic Centers
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Bristol-Meyrs Squibb Company
6.1.3 GlaxoSmithKline PLC
6.1.4 Merck & Co. Inc.
6.1.5 Pfizer Inc.
6.1.6 Qiagen NV
6.1.7 Advaxis Inc.
6.1.8 Becton, Dickinson and Company
6.1.9 F. Hoffmann-La Roche Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS